Considering the crucial importance of cellular migration (leading to metastasis) for patient survival, it seems odd that in the past decades, therapeutic approaches for stage IV metastatic disease mainly focused on interference with melanoma cell proliferation (chemotherapy, radiation), on immunological stimulation (vaccination, blocking of CTLA-4), or on oncogene-targeted therapy (e.g. BRAF V600E mutation [3]) available only for a subpopulation of melanomas. The gene discussed is CTLA4; the disease is melanoma.